Chemical formula: C₁₆H₁₇N₅O₇S₂ Molecular mass: 455.465 g/mol PubChem compound: 5742673
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby inhibiting cell wall synthesis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01DD01 | Cefotaxime | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DD Third-generation cephalosporins |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CEFOTAXIME 1g Powder for solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Cefotaxime is an active ingredient of these brands:
Austria (AT)
Brazil (BR)Estonia (EE)Hong Kong (HK)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)Mexico (MX)
Poland (PL)
Singapore (SG)
South Africa (ZA)
Spain (ES)Tunisia (TN)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
